Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide ( VP16 ) or Doxorubicin on A2774 human epithelial ovarian cancer cell line .
Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide ( VP16 ) or Doxorubicin on A2774 human epithelial ovarian cancer cell line . Recombinant human tumor necrosis factor (rHuTNF) is a cytokine, with some antitumor activity, released by stimulated monocytes-macrophages. In vivo and in vitro cytotoxicity studies testing the effectiveness of rHuTNF alone or in combination with chemotherapeutic agents have been carried out. We have evaluated the direct cytotoxic effect of rHuTNF on a human epithelial ovarian cancer cell line in vitro (A2774), alone or in combination with etoposide (VP16) or doxorubicin (Doxo), some topoisomerase II (Topo II) targeted drugs, or in combination with cisplatin (CDDP), a not Topo II interactive drug. Our results suggest that rHuTNF is directly cytotoxic and that it is also able to induce a potentiation of VP16- or Doxo-cytotoxicity, but it is unable to potentiate CDDP-cytotoxicity. These data represent a reasonable basis for combining rHuTNF with Topo II inhibitors within phase I studies. The combination regimen could be tested in ovarian cancer patients.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide ( VP16 ) or Doxorubicin on A2774 human epithelial ovarian cancer cell line . Recombinant human tumor necrosis factor (rHuTNF) is a cytokine, with some antitumor activity, released by stimulated monocytes-macrophages. In vivo and in vitro cytotoxicity studies testing the effectiveness of rHuTNF alone or in combination with chemotherapeutic agents have been carried out. We have evaluated the direct cytotoxic effect of rHuTNF on a human epithelial ovarian cancer cell line in vitro (A2774), alone or in combination with etoposide (VP16) or doxorubicin (Doxo), some topoisomerase II (Topo II) targeted drugs, or in combination with cisplatin (CDDP), a not Topo II interactive drug. Our results suggest that rHuTNF is directly cytotoxic and that it is also able to induce a potentiation of VP16- or Doxo-cytotoxicity, but it is unable to potentiate CDDP-cytotoxicity. These data represent a reasonable basis for combining rHuTNF with Topo II inhibitors within phase I studies. The combination regimen could be tested in ovarian cancer patients.

            ### Response:
            human tumor necrosis factor, Etoposide, Doxorubicin
            